Many are outraged that Eli Lilly gave nonprofits $3.9 million in grants last year for medical courses to "educate" doctors about the pain-and-fatigue ailment fibromyalgia--more than it spent for diabetes and Alzheimer's which people already know they have.
But finding new diseases to justify a drug's existence is the normal way pharma operates.
Especially Lilly who agreed to pay $1.42 billion for illegal marketing of its anti-psychotic Zyprexa last month--$615 million for criminally promoting it for dementia--another $62 million to 32 states for illegal pediatric marketing and agreed to resolve Medicaid fraud investigations into "rebates" at the same time. (And how was your year?)
And whose diabetes treatment Byetta is tanking since reports last summer of six deaths, at least two from pancreatitis.
But Lilly's fibromyalgia-fighting drug, Cymbalta (duloxetine)--its second best seller after Zyprexa--is anything but normal.
Starting with the death of 19-year-old Cymbalta test subject Traci Johnson in 2004--who hanged herself in the Lilly Clinic in Indianapolis and had no history of mental problems--it has been beset by reports of baffling, rapid, unprovoked, and out of character suicides and suicide attempts.
READ MORE @ COUNTERPUNCH
Showing posts with label Cymbalta. Show all posts
Showing posts with label Cymbalta. Show all posts
Wednesday, February 18, 2009
Wednesday, January 14, 2009
New Study: Antidepressants Help Patients with Fibromyalgia
Drugs traditionally used to treat depression are also effective in easing widespread pain, sleep disturbances and dismal moods associated with fibromyalgia syndrome (FMS), according to a large-scale analysis published today in JAMA The Journal of the American Medical Association. The study confirms earlier research about the meds' effect on symptoms associated with this mysterious disease.
Fibromyalgia, an often overlooked disorder believed to cause widespread muscle pain, sleep disturbances, depression and fatigue, affects up to 12 million people (4 percent of the U.S. population), nearly 11 million of them women. The degree of debilitation caused by the disease ranges "from very little to total," says Roland Staud, a professor of medicine at the University of Florida College of Medicine in Gainesville, adding that he has known some patients who have been bedridden for as long as a year because of symptoms, which typically appear between ages 40 and 60 and may last for the remainder of sufferers' lives.
Researchers do not know the cause of FMS and there is currently no cure. But psychiatrist Leslie Arnold, director of the Women's Health Research Program at the University of Cinncinnati's College of Medicine, says that both genetics and stress appear to play a role. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) to treat fibromyalgia—Cymbalta made by Eli Lilly (one of the antidepressants reviewed in this study) and Pfizer's Lyrica, an Rx to control seizures and pain.
READ MORE @ SCIENTIFIC AMERICAN
Fibromyalgia, an often overlooked disorder believed to cause widespread muscle pain, sleep disturbances, depression and fatigue, affects up to 12 million people (4 percent of the U.S. population), nearly 11 million of them women. The degree of debilitation caused by the disease ranges "from very little to total," says Roland Staud, a professor of medicine at the University of Florida College of Medicine in Gainesville, adding that he has known some patients who have been bedridden for as long as a year because of symptoms, which typically appear between ages 40 and 60 and may last for the remainder of sufferers' lives.
Researchers do not know the cause of FMS and there is currently no cure. But psychiatrist Leslie Arnold, director of the Women's Health Research Program at the University of Cinncinnati's College of Medicine, says that both genetics and stress appear to play a role. Only two drugs have been approved by the U.S. Food and Drug Administration (FDA) to treat fibromyalgia—Cymbalta made by Eli Lilly (one of the antidepressants reviewed in this study) and Pfizer's Lyrica, an Rx to control seizures and pain.
READ MORE @ SCIENTIFIC AMERICAN
Thursday, August 2, 2007
Lilly Posts Ends Strong Numbers With Cialis, Cymbalta
Eli announced its second quarter results, reporting sales were up 20 percent, worldwide. Eli Lilly reported Q2 sales reached $4.63 billion, with volume up 11 percent, led by the antidepressant drug Cymbalta and the erectile dysfunction drug Cialis.
In January, Eli Lilly acquired Cialis' maker, ICOS Corp. for $2.3 billion. The second quarter return is the first full period incorporating Cialis profits into Eli Lilly's numbers. The take-over kicked marketing and administrative expenses up 23 percent to $1.52 billion.
"We are very pleased to have delivered another quarter of strong financial results," CEO Sidney Taurel said. "Our accelerated, double-digit sales growth in this quarter was fueled by increased volume, driven by several products launched this decade, most notably Cymbalta."
In January, Eli Lilly acquired Cialis' maker, ICOS Corp. for $2.3 billion. The second quarter return is the first full period incorporating Cialis profits into Eli Lilly's numbers. The take-over kicked marketing and administrative expenses up 23 percent to $1.52 billion."We are very pleased to have delivered another quarter of strong financial results," CEO Sidney Taurel said. "Our accelerated, double-digit sales growth in this quarter was fueled by increased volume, driven by several products launched this decade, most notably Cymbalta."
Subscribe to:
Posts (Atom)
